GALACTIC-HF

#AHA20

AMERICAN COLLEGE of CARDIOLOGY

Trial Description: Patients with symptomatic chronic HFrEF ≤35% were randomized to omecamtiv mecarbil (selective cardiac myosin activator) or placebo in addition to standard HF therapy.



RESULTS

- Primary composite endpoint of HF event or CV death at a median of 21.8 months: omecamtiv mecarbil vs. placebo: 37.0% vs. 39.1% (p = 0.03)
- Benefit was generally consistent across most pre-specified subgroup analyses; however, there was heterogeneity seen for baseline EF with greater treatment effect with LVEF ≤28%

CONCLUSIONS

- In patients with HFrEF, omecamtiv mecarbil showed a statistically significant reduction in the risk of the primary composite outcome (first HF event or CV death)
- No difference was seen in CV death, all-cause death, or change in KCCQ total symptom score
- No major safety issues were identified with the use of omecamtiv mecarbil

Teerlink JR, et al. N Eng J Med 2021;384:105-16.